Suppr超能文献

华法林相关大出血患者的国际标准化比值(INR)未得到纠正与死亡率:电子健康记录分析。

Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records.

机构信息

Outcomes Research, Boston Health Economics, Inc, Waltham, MA 02451, USA.

出版信息

J Thromb Haemost. 2012 Apr;10(4):596-605. doi: 10.1111/j.1538-7836.2012.04636.x.

Abstract

BACKGROUND

Delayed correction of blood clotting times as measured by the International Normalized Ratio (INR) is associated with adverse outcomes among certain patients with warfarin-related major bleeding. However, there are limited data on the association between INR correction and mortality.

OBJECTIVE

To assess factors associated with 30-day mortality and time to death in patients receiving fresh frozen plasma (FFP) for warfarin-associated major bleeding.

METHODS

A retrospective database analysis was undertaken with electronic health record data from a large integrated health system. Patients met the following criteria: major hemorrhage diagnosis; INR ≥ 2 on the day before or day of receipt of FFP; and prescription fill for warfarin within 90 days. INR correction (defined as INR ≤ 1.3) was evaluated at the last available test 1 day following the start of FFP administration. Kaplan-Meier curves and Cox proportional hazards models were constructed to assess mortality.

RESULTS

Four hundred and five patients met the selection criteria (mean age of 75 years, 54% male), and 67% remained uncorrected at 1 day following the start of FFP administration. Among all patients, 11% died within 30 days of hospital admission. An uncorrected INR was not associated with a higher risk of 30-day mortality for patients overall, but was statistically significant for the subgroup with intracranial hemorrhage (ICH) (adjusted odds ratio 2.55; 95% confidence interval 1.04-6.28).

CONCLUSIONS

Among the subgroup of major bleeding patients with warfarin-associated ICH, those not correcting to either INR ≤ 1.3 or INR ≤ 1.5 with the use of FFP have an increased rate of mortality at 30 days.

摘要

背景

国际标准化比值(INR)测量的凝血时间延迟校正与某些华法林相关大出血患者的不良结局相关。然而,关于 INR 校正与死亡率之间的关联的数据有限。

目的

评估接受新鲜冷冻血浆(FFP)治疗华法林相关大出血患者的 INR 校正与 30 天死亡率和死亡时间之间的关系。

方法

对来自大型综合健康系统的电子健康记录数据进行回顾性数据库分析。患者符合以下标准:主要出血诊断;在接受 FFP 的前一天或当天 INR≥2;并且在 90 天内开具华法林处方。在开始 FFP 治疗后的第 1 天,最后一次可用测试时评估 INR 校正(定义为 INR≤1.3)。构建 Kaplan-Meier 曲线和 Cox 比例风险模型来评估死亡率。

结果

405 名患者符合选择标准(平均年龄 75 岁,54%为男性),67%的患者在开始 FFP 治疗后第 1 天仍未校正。在所有患者中,11%的患者在入院后 30 天内死亡。未校正的 INR 与所有患者的 30 天死亡率没有更高的风险相关,但对于颅内出血(ICH)亚组具有统计学意义(校正比值比 2.55;95%置信区间 1.04-6.28)。

结论

在伴有华法林相关 ICH 的大出血患者亚组中,使用 FFP 未将 INR 校正至 INR≤1.3 或 INR≤1.5 的患者在 30 天时死亡率更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验